US FDA declines to approve AbbVie’s Parkinson’s disease therapy
(Reuters) – AbbVie Inc said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson’s disease therapy for adults and had requested for more information on the device used to administer the treatment. The therapy, ABBV-951, is a formulation of carbidopa-levodopa, the standard of care for the disease. It is administered …
US FDA declines to approve AbbVie’s Parkinson’s disease therapy Read More »